Poolbeg Pharma has completed an Initial Public Offering on AIM
Poolbeg Pharma Plc has raised funds to develop the company.
Poolbeg Pharma is a clinical-stage, infectious disease pharmaceutical company with a capital light clinical model which aims to develop multiple products faster and more cost-effectively than the conventional biotech model, aspiring to become a one-stop shop for Big Pharma seeking mid-stage products to license or acquire. The company was formed from a spin-out of assets from Open Orphan Plc and is headquartered in London, UK.
Oaklins Cavendish’s sister firm finnCap, based in the UK, in its role as IPO advisor, assisted Poolbeg Pharma’s management team and shareholders all the way from the start to the successful completion of the IPO. During this process, the team initiated and advised on many aspects, including, among others, securing commitments from investors, asset spin out deal structuring, EIS eligibility, and the IPO pricing and sizing.
Talk to the deal team
Managing DirectorLondon, United Kingdom
PartnerLondon, United Kingdom
East West Eye Institute has been acquired by NVISION Eye Centers
East West Eye Institute (EWEI), one of the largest independent eyecare platforms in California, has sold a majority interest to Nvision Eye Centers, one of the larger providers of comprehensive eyecare, LASIK and cataract surgery services in the USA.Learn more
UAB MediCA klinika has acquired UAB Varpo seimos klinika
UAB MediCA klinika has acquired UAB Varpo seimos klinika.Learn more
GBM Resources (ASX:GBZ) has raised US$5.4 million via a placement
GBM Resources Limited has raised funds to accelerate drilling at the flagship Drummond Basin, along with funding the acquisition of Twin Hills.Learn more